These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33835429)

  • 1. Haloperidol as an anti-emetic for Cannabis Hyperemesis Syndrome in the ED.
    Trajkovski A; Lang E
    CJEM; 2021 May; 23(3):312-313. PubMed ID: 33835429
    [No Abstract]   [Full Text] [Related]  

  • 2. Haloperidol for treatment of cannabinoid hyperemesis syndrome.
    Hickey JL; Witsil JC; Mycyk MB
    Am J Emerg Med; 2013 Jun; 31(6):1003.e5-6. PubMed ID: 23583118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
    Inayat F; Virk HU; Ullah W; Hussain Q
    BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
    Ruberto AJ; Sivilotti MLA; Forrester S; Hall AK; Crawford FM; Day AG
    Ann Emerg Med; 2021 Jun; 77(6):613-619. PubMed ID: 33160719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
    Moussa G; Genest M; Villeneuve E; Wang JJ
    Ann Emerg Med; 2021 May; 77(5):555. PubMed ID: 33902836
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.
    Smith TN; Walsh A; Forest CP
    JAAPA; 2019 Apr; 32(4):1-5. PubMed ID: 30913155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis hyperemesis syndrome.
    Sharma U
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30323105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Cannabis Hyperemesis Syndrome Using Haloperidol in a Pregnant Patient: Case Report.
    La Sala MS; Constantino E; Koola MM; Yel I; Chacko M
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):506-508. PubMed ID: 35943399
    [No Abstract]   [Full Text] [Related]  

  • 9. Cannabinoid hyperemesis syndrome.
    Galli JA; Sawaya RA; Friedenberg FK
    Curr Drug Abuse Rev; 2011 Dec; 4(4):241-9. PubMed ID: 22150623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.
    Witsil JC; Mycyk MB
    Am J Ther; 2017; 24(1):e64-e67. PubMed ID: 25393073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.
    Lee C; Greene SL; Wong A
    Clin Toxicol (Phila); 2019 Sep; 57(9):773-777. PubMed ID: 30729854
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.
    Venkatesan T; Levinthal DJ; Li BUK; Tarbell SE; Adams KA; Issenman RM; Sarosiek I; Jaradeh SS; Sharaf RN; Sultan S; Stave CD; Monte AA; Hasler WL
    Neurogastroenterol Motil; 2019 Jun; 31 Suppl 2(Suppl 2):e13606. PubMed ID: 31241817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.
    Rock EM; Bolognini D; Limebeer CL; Cascio MG; Anavi-Goffer S; Fletcher PJ; Mechoulam R; Pertwee RG; Parker LA
    Br J Pharmacol; 2012 Apr; 165(8):2620-34. PubMed ID: 21827451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid Hyperemesis Syndrome and the Consulting Psychiatrist: A Case Study of Diagnosis and Treatment for an Emerging Disorder in Psychiatric Practice.
    Kast KA; Gershengoren L
    J Psychiatr Pract; 2018 Jan; 24(1):51-55. PubMed ID: 29320384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing and treating cannabinoid hyperemesis.
    Wilson O; Lutton S; Doherty K
    Emerg Nurse; 2015 Dec; 23(8):22-5. PubMed ID: 26638755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer.
    Hardy JR; O'Shea A; White C; Gilshenan K; Welch L; Douglas C
    J Pain Symptom Manage; 2010 Jul; 40(1):111-6. PubMed ID: 20619214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.
    Machado Rocha FC; Stéfano SC; De Cássia Haiek R; Rosa Oliveira LM; Da Silveira DX
    Eur J Cancer Care (Engl); 2008 Sep; 17(5):431-43. PubMed ID: 18625004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
    Stuart-Harris RC; Mooney CA; Smith IE
    Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-emetic effect of granisetron in patients undergoing cranial and craniospinal radiotherapy].
    Yamasaki F; Watanabe Y; Nosaka R; Kenjo M; Nakamura K; Takayasu T; Saito T; Tominaga A; Sugiyama K; Kurisu K
    No Shinkei Geka; 2014 Jan; 42(1):27-34. PubMed ID: 24388937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review.
    Richards JR; Gordon BK; Danielson AR; Moulin AK
    Pharmacotherapy; 2017 Jun; 37(6):725-734. PubMed ID: 28370228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.